Fda Fibromyalgia Public Meeting On Patient-Focused Drug Development

[FibroDiva 60]

The food and Drug Administration [FDA] is presenting an opportunity for our voices to be heard.

On December 10, 2013, FDA is conducting a public meeting on Fibromyalgia Patient-Focused Drug Development. FDA is interested in obtaining patient input on the impact of fibromyalgia on daily life (topic 1) and currently available therapies to treat the condition (topic 2). The questions for discussion on these topics are located at the bottom of this page.

For each of these topics, a panel of patients and patient representatives/advocates will present comments to begin the dialogue and will be followed by a facilitated discussion inviting comments from other patients and patient representatives.

If you are interested in providing comments as part of the initial panel discussion, indicate so during the registration process. Participants for the panel discussions will be confirmed prior to the meeting.

There will also be an opportunity for patients, patient representatives and others to provide comments on issues other than topics 1 and 2 during an Open Public Comment session. Sign up for Open Public Comment will take place the day of the meeting.

Don't worry if you cannot physically attend the meeting in Maryland, you can attend via webcast also.

click here for more information.